Selective JAK1 Inhibitor Structure for Reduced Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK enzyme inhibitors have significant side effects due to their non-selective inhibition of JAK3, leading to issues like infections and anemia, and there is a need for high selectivity inhibitors for JAK1 to mitigate these side effects.
Innovation Solution
A novel JAK inhibitor compound with a specific structure, represented by formula I, which exhibits improved selectivity for JAK3/JAK1 or JAK3/JAK2, reducing side effects associated with JAK3 inhibition and enhancing safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing JAK enzyme inhibitors are used to treat inflammatory and autoimmune diseases, then therapeutic effects are achieved, but serious side effects occur due to non-selective inhibition of JAK3
Solution Approach 1:
The patent applies local quality by designing a inhibitor with specific structural features (formula I) that create different binding characteristics for JAK1 versus JAK3. The compound selectively targets JAK1's active site while having reduced affinity for JAK3, thereby achieving localized inhibition effect that preserves JAK3 function and avoids its associated side effects while maintaining therapeutic efficacy through JAK1 inhibition.
Solution Approach 2:
The patent employs parameter changes by modifying chemical parameters of the inhibitor structure (formula I) to alter its binding properties. By adjusting structural parameters such as substituent groups and molecular configuration, the compound achieves optimal selectivity parameters for JAK1 over JAK3, transforming the inhibition profile from non-selective to selective while maintaining therapeutic effectiveness.
2Adaptability or versatility
If JAK1 and JAK3 are both inhibited to achieve broad therapeutic coverage, then multiple disease conditions are treated, but immunity is compromised and infections occur
Solution Approach 1:
The patent applies the taking out principle by extracting the JAK1 inhibition function from the combined JAK1/JAK3 inhibition effect. The compound selectively isolates and targets only the JAK1 pathway while leaving JAK3 activity intact, thereby separating the therapeutic benefits of JAK1 inhibition from the harmful immune suppression caused by JAK3 inhibition, achieving broad therapeutic coverage without compromising immunity.
3Object-affected harmful factors
If high selectivity for JAK1 is achieved through structural optimization, then side effects are reduced, but development difficulty increases due to common γ-chain cytokine receptor complex
Solution Approach 1:
The patent applies parameter changes by systematically optimizing chemical parameters of the inhibitor structure (formula I) to achieve the desired selectivity profile. Through iterative modification of structural parameters and evaluation of binding characteristics, the compound achieves high JAK1 selectivity despite the structural similarities in the common γ-chain cytokine receptor complex, balancing selectivity achievement with development feasibility.
Data Source
AI summary
Provided in the present invention are a new type JAK kinase selective inhibitor and a preparation method and the use thereof. In particular, disclosed are a compound having the structure as shown in chemical formula (I) as a JAK kinase inhibitor or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.